Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
437.00    -9.00 (-2.02%)
Bid:
436.50
Ask:
440.50
Spread: 4.00 (0.916%)
Market Cap: £214.92m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

25 May 2022 07:00

RNS Number : 6535M
Zotefoams PLC
25 May 2022
 

Zotefoams plc

("Zotefoams" or "Group")

 

Trading Update

 

25 May 2022 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the four months ended 30 April 2022 ahead of its Annual General Meeting to be held today at 10am at 675 Mitcham Road, Croydon, CR9 3AL.

At this meeting Steve Good, Chair of Zotefoams plc, will make the following statement:

In line with the outlook statement in our 2021 preliminary results announcement, we have experienced good demand in the first four months of 2022, resulting in Group revenue for the period being approximately 13% ahead of the comparative period.

Highlights in the period are:

Polyolefin Foams sales increased by 20%. Volumes have increased by 5%, with the majority of the sales uplift being driven by increased prices

High-Performance Products (HPP) sales increased by 6%:

Footwear sales at similar levels to prior period, as expected at this point in the demand cycle

Aviation sales improving strongly from a low base

T-FIT® insulation products sales increased by 18%

MuCell Extrusion's focus is on the technical and commercial development of ReZorce® mono-material packaging solutions, with good progress in the period

The macroeconomic environment remains difficult, with input cost inflation both significant and unpredictable and supply chains prone to disruption. We have been reacting to input-price movements by increasing our selling prices as well as focusing on internal efficiencies and controllable costs, while proactively implementing actions to mitigate supply chain risks. There has been no material disruption to the Footwear supply chain or to our major facilities in the UK, USA and Poland, although there was a 5-week enforced shutdown of our China T-FIT facility due to COVID-19.

Outlook

We have delivered good sales growth in the first four months of the year and anticipate this sales momentum to continue, supported by the price increases and a strong order book with excellent visibility to the end of June. However, we do not anticipate the challenging macroeconomic environment to ease and remain mindful of some specific risks around COVID-19.

While it is still early in the year, we anticipate Group revenue to be ahead of market expectations for the full year, with demand in line and higher prices recovering cost inflation. Current foreign exchange rates, net of hedging, may also provide some additional benefit. Consequently, we are comfortable with expectations for growth in profit and remain confident about the long-term prospects of the business.

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"Zotefoams products are well positioned to deliver benefits to society by saving energy, protecting people and goods and helping our customers make their products using less raw material. We have invested significantly in recycling initiatives with ReZorce barrier packaging and in our core foams business, and we are well placed for future growth. The current macroeconomic climate is extremely challenging and I am proud of our team for balancing customer expectations with the cost inflation and supply chain pressures we face as a business. 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

www.zotefoams.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKZGZKDDRGZZM
Date   Source Headline
15th Aug 201312:26 pmRNSDirector/PDMR Shareholding
6th Aug 20137:00 amRNSHalf Yearly Report
12th Jul 20139:29 amRNSJoint Venture in Asia
8th Jul 20137:00 amRNSTrading Update
3rd Jun 201311:37 amRNSDirector/PDMR Shareholding
21st May 20139:43 amRNSDirector/PDMR Shareholding
15th May 201312:02 pmRNSResult of AGM
15th May 20137:00 amRNSAGM Statement and Interim Management Statement
29th Apr 20134:27 pmRNSDirector/PDMR Shareholding
10th Apr 20135:45 pmRNS2012 Annual Report and Accounts and AGM Notice
10th Apr 20132:22 pmRNSHolding(s) in Company (Replacement)
26th Mar 20131:01 pmRNSHolding(s) in Company
19th Mar 20135:43 pmRNSDirector/PDMR Shareholding
19th Mar 20135:40 pmRNSDirector/PDMR Shareholding
15th Mar 201310:00 amRNSHolding(s) in Company
12th Mar 20139:19 amRNSDirector/PDMR Shareholding
5th Mar 20137:00 amRNSFinal Results
18th Feb 20133:14 pmRNSChange of Advisers
9th Jan 20137:00 amRNSTrading Update
14th Nov 20129:56 amRNSDirector Declaration
26th Oct 20127:00 amRNSInterim Management Statement
14th Aug 201211:58 amRNSNotification of Major Interest in shares
14th Aug 20127:00 amRNSMuCell Extrusion LLC Obtains an Exclusive License
7th Aug 20127:02 amRNSHalf Yearly Report
7th Aug 20127:00 amRNSDow and MuCell Extrusion LLC Enter Agreement
9th Jul 20127:00 amRNSTrading Update
12th Jun 201212:15 pmRNSDirector/PDMR Shareholding
10th May 201212:08 pmRNSResult of AGM
10th May 20127:00 amRNSAGM and Interim Management Statement
13th Apr 201212:31 pmRNSHolding(s) in Company
13th Apr 201210:43 amRNSDirector/PDMR Shareholding
5th Apr 20123:25 pmRNSAnnual Information Update
5th Apr 201212:23 pmRNS2011 Annual Report & Accounts and Notice of AGM
5th Apr 201210:31 amRNSDirector/PDMR Shareholding
28th Mar 20128:43 amRNSHolding(s) in Company
6th Mar 20127:00 amRNSFinal Results
27th Jan 201210:57 amRNSHolding(s) in Company
19th Jan 20124:48 pmRNSHolding(s) in Company
9th Jan 20127:00 amRNSTrading Statement
13th Dec 20113:27 pmRNSDirector/PDMR Shareholding
22nd Nov 20117:00 amRNSDirector/PDMR Shareholding
28th Oct 20112:18 pmRNSHolding(s) in Company
24th Oct 20117:00 amRNSInterim Management Statement
16th Sep 20112:35 pmRNSHolding(s) in Company
2nd Aug 20117:00 amRNSHalf Yearly Report
5th Jul 20117:00 amRNSTrading Update
16th Jun 20117:00 amRNSDirectorate Appointments
7th Jun 20119:13 amRNSAnnual Information Update
13th May 20112:10 pmRNSHolding(s) in Company
13th May 201110:34 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.